LOS ANGELES<\/span><\/span>, March 4, 2025<\/span><\/span> \/PRNewswire\/ — The\u00a0Schall Law Firm<\/a><\/u>, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI<\/a>) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b<\/span>-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p>\n Investors who purchased the Company’s securities between August 7, 2024<\/span> and February 24, 2025<\/span>, inclusive (the “Class Period”), are encouraged to contact the firm before May 5<\/span>, 2025.\u00a0<\/p>\n If you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>\n We also encourage you to contact Brian Schall<\/span> of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA<\/span> 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at\u00a0www.schallfirm.com<\/a><\/u>, or by email at\u00a0[email\u00a0protected]<\/span><\/a>.<\/p>\n The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.<\/p>\n According to the Complaint, the Company made false and misleading statements to the market. Maravai failed to maintain adequate internal controls over financial reporting. The Company improperly recognize revenue from certain transactions in fiscal 2024. The Company overstated its goodwill. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Maravai, investors suffered damages.<\/p>\n Join the case<\/a> to recover your losses.<\/p>\n The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.<\/p>\n This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n CONTACT:<\/b><\/p>\n The Schall Law Firm SOURCE The Schall Law Firm<\/p>\n LOS ANGELES, March 4, 2025 \/PRNewswire\/ — The\u00a0Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against\u00a0Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and […]<\/p>\n","protected":false},"author":1,"featured_media":23066,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[204],"tags":[],"class_list":["post-23065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/posts\/23065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/comments?post=23065"}],"version-history":[{"count":0,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/posts\/23065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/media\/23066"}],"wp:attachment":[{"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/media?parent=23065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/categories?post=23065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvrising.com\/blogs\/wp-json\/wp\/v2\/tags?post=23065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Brian Schall, Esq.<\/span>,
www.schallfirm.com<\/a>
Office: 310-301-3335
[email\u00a0protected]<\/span><\/a><\/u><\/p>\n![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA33576&Transmission_Id=202503042047PR_NEWS_USPR_____LA33576&DateId=20250304\")
<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"